TeraRecon Launches AI-Powered Neuro Suite
The artificial intelligence (AI)-powered Neuro Suite reportedly enables radiologists to access leading neurological AI algorithm solutions in the field, including the brain magnetic resonance imaging (MRI) segmentation capabilities of the Combinostics’ algorithm that can help differentiate degenerative pathologies such as Alzheimer’s disease and dementia.
Emphasizing timely neurological disease triage and access to “a first-in-class capability and the only open (artificial intelligence) AI architecture” for clinical AI, ConcertAI’s TeraRecon has launched Neuro Suite.
The Neuro Suite platform allows radiologists to access a variety of AI-powered neuroimaging modalities from leading vendors in the neurology field, including Combinostics, Imaging Biometrics and Cercare Medical, according to TeraRecon.
For the diagnosis of degenerative cerebral pathologies including Alzheimer’s disease and dementia, the Combinostics algorithm offers high-quality segmentation of brain magnetic resonance imaging (MRI) to help assess atrophy. TeraRecon said the algorithm from Imaging Biometrics provides radiologists with insights into the blood supply and oxygenation of brain tumors. Access to the proprietary perfusion technology of Cercare Medical enables neurovascular function assessment down to the capillary level, according to TeraRecon.
“We are proud to enhance our neurological offerings beyond TR Neuro to an entire Neuro Suite, extending to our clinician customers an amazing array of tools streamlined into one place and able to be interacted with to help identify and treat critical neurological issues,” said Dan McSweeney, the president of TeraRecon.
(Editor’s note: For related content, see “TeraRecon Launches AI-Driven Neuroimaging Platform” and “FDA Clears AI-Enabled Software for Streamlining Brain MRI Assessment and Reporting.”)
FDA Clears Enhanced MRI-Guided Laser Ablation System
June 5th 2025An alternative to an open neurosurgical approach, the Visualase V2 MRI-Guided Laser Ablation System reportedly utilizes laser interstitial thermal therapy (LITT) for targeted soft tissue ablation in patients with brain tumors and focal epilepsy.
Can Abbreviated MRI Have an Impact in Differentiating Intraductal Papilloma and Ductal Secretion?
June 3rd 2025For patients with inconclusive ultrasound results, abbreviated breast MRI offers comparable detection of intraductal papilloma as a full breast MRI protocol at significantly reduced times for scan acquisition and interpretation, according to a new study.
Can AI Assessment of PET Imaging Predict Treatment Outcomes for Patients with Lymphoma?
June 2nd 2025The use of adjunctive AI software with pre-treatment PET imaging demonstrated over a fourfold higher likelihood of predicting progression-free survival (PFS) in patients being treated for lymphoma, according to a new meta-analysis.
